ClinicalTrials.gg
RecruitingNCT07448597Updated Aug 17, 2026

Progesterone Preeclampsia

A Phase 4 interventional study of Progesterone supplementation in Preeclampsia and Hypertensive Disorder of Pregnancy, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Medical University of South Carolina · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
642
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 230 studies in Pre-Eclampsia with a site in United States — 62 open to participants now, 78 under way, 6 of them phase 3. Pre-Eclampsia · United States.

Planned enrollment
15th of 161
642 · median 89
Started
2026
with 26 others
Phase 4
31 of 230
11 open now
Primary completion
2028-08
later than 59 of 77 live
Registered
215th of 230
by date

Among the 230 studies in Pre-Eclampsia with a site in United States, this one is the 15th largest by planned enrollment of the 161 interventional ones that give a count, is one of 27 that started in 2026, is one of 31 in phase 4, reaches primary completion later than 59 of the 77 other live ones, and was the 215th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

62 of the 230 studies in Pre-Eclampsia with a site in United States are open now. Recruiting first, the newest first:

56 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Pre-Eclampsia with a site in United States, or all of them as a file.
02

Study summary

This randomized controlled trial evaluates whether nightly vaginal micronized progesterone (400 mg) initiated before 12 weeks' gestation reduces the incidence of preeclampsia in low-risk pregnant individuals. Participants will be randomly assigned (1:1) to receive either vaginal progesterone through 16 weeks' gestation or routine prenatal care without progesterone. Maternal and neonatal outcomes-including development of preeclampsia, obstetric complications, gestational diabetes, preterm birth, and neonatal morbidity-will be collected via chart review. The study aims to determine whether early progesterone supplementation decreases the risk of preeclampsia.

03

Conditions studied

  • Preeclampsia
  • Hypertensive Disorder of Pregnancy

Browse trials for

Keywords

  • Progesterone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant individuals receiving prenatal care at participating clinics
  • \<12 weeks gestation with a viable intrauterine pregnancy
  • Age ≥18 years
  • English-speaking

Exclusion criteria

Exclusion Criteria:

  • Unable or unwilling to self-administer vaginal progesterone
  • Inability or unwillingness to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
642 participants (estimated)

Study arms

  • No intervention
    Control
  • Experimental
    Progesterone

    Drug: Progesterone supplementation

Interventions

  • DrugProgesterone supplementation

    Patients in the progesterone arm will be randomized to receive progesterone supplementation while the control arm will not receive any additional intervention.

06

What researchers measure

Primary outcomes

  1. Development of preeclampsia

    Defined as new onset systolic blood pressure ≥ 140 or diastolic blood pressure ≥ 90 on two occasions at least 4 hours apart, after 20 weeks gestation, with proteinuria or evidence of maternal acute kidney impairment, liver dysfunction, neurologic features, hemolysis, or thrombocytopenia

    Time frame: Antenatally and up to 6 weeks postpartum

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2028, 23 months after the start.

Of 35 phase 4 interventional studies under Pre-Eclampsia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 35. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 4, 2026
StartActual
Aug 13, 2026
Primary completionEst.
Aug 1, 2028
CompletionEst.
Aug 1, 2028
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07448597
Responsible party
Brittany Austin (Assistant Professor-Faculty, Medical University of South Carolina) — Principal investigator
First posted
Mar 4, 2026
Start date
Aug 13, 2026
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Aug 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion